Stay updated on Dara-Thal-Dex in Relapse Myeloma Clinical Trial
Sign up to get notified when there's something new on the Dara-Thal-Dex in Relapse Myeloma Clinical Trial page.

Latest updates to the Dara-Thal-Dex in Relapse Myeloma Clinical Trial page
- Check4 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check25 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check54 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check69 days agoChange DetectedThe webpage has been updated to reflect a new phase 2 study of the combination treatment of Daratumumab, thalidomide, and dexamethasone for relapse or refractory myeloma, including details about the study's collaborators and principal investigator. Additionally, some outdated information regarding previous treatments and survival rates has been removed.SummaryDifference42%
- Check76 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Dara-Thal-Dex in Relapse Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dara-Thal-Dex in Relapse Myeloma Clinical Trial page.